Literature DB >> 17351763

RNAi-dependent and -independent antiviral phenotypes of chromosomally integrated shRNA clones: role of VASP in respiratory syncytial virus growth.

Alla Musiyenko1, Vira Bitko, Sailen Barik.   

Abstract

Stable RNA interference (RNAi) is commonly achieved by recombinant expression of short hairpin RNA (shRNA). To generate virus-resistant cell lines, we cloned a shRNA cassette against the phosphoprotein gene of respiratory syncytial virus (RSV) into a polIII-driven plasmid vector. Analysis of individual stable transfectants showed a spectrum of RSV resistance correlating with the levels of shRNA expressed from different chromosomal locations. Interestingly, resistance in a minority of clones was due to mono-allelic disruption of the cellular gene for vasodilator-stimulated phosphoprotein (VASP). Thus, pure clones of chromosomally integrated DNA-directed RNAi can exhibit gene disruption phenotypes resembling but unrelated to RNAi.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351763      PMCID: PMC3263383          DOI: 10.1007/s00109-007-0179-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  23 in total

1.  The contributions of dsRNA structure to Dicer specificity and efficiency.

Authors:  Annaleen Vermeulen; Linda Behlen; Angela Reynolds; Alexey Wolfson; William S Marshall; Jon Karpilow; Anastasia Khvorova
Journal:  RNA       Date:  2005-04-05       Impact factor: 4.942

Review 2.  Silence of the transcripts: RNA interference in medicine.

Authors:  Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2005-07-19       Impact factor: 4.599

Review 3.  Lessons from Nature: microRNA-based shRNA libraries.

Authors:  Kenneth Chang; Stephen J Elledge; Gregory J Hannon
Journal:  Nat Methods       Date:  2006-09       Impact factor: 28.547

Review 4.  Expressing short hairpin RNAs in vivo.

Authors:  Ola Snøve; John J Rossi
Journal:  Nat Methods       Date:  2006-09       Impact factor: 28.547

5.  Inhibition of respiratory viruses by nasally administered siRNA.

Authors:  Vira Bitko; Alla Musiyenko; Olena Shulyayeva; Sailen Barik
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

Review 6.  Prospects of RNA interference therapy in respiratory viral diseases: update 2006.

Authors:  Sailen Barik; Vira Bitko
Journal:  Expert Opin Biol Ther       Date:  2006-11       Impact factor: 4.388

7.  Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs.

Authors:  Sergio Carmona; Abdullah Ely; Carol Crowther; Naazneen Moolla; Felix H Salazar; Patricia L Marion; Nicolas Ferry; Marc S Weinberg; Patrick Arbuthnot
Journal:  Mol Ther       Date:  2005-12-05       Impact factor: 11.454

8.  Adeno-associated virus vectors for short hairpin RNA expression.

Authors:  Dirk Grimm; Kusum Pandey; Mark A Kay
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

9.  Functional polarity is introduced by Dicer processing of short substrate RNAs.

Authors:  Scott D Rose; Dong-Ho Kim; Mohammed Amarzguioui; Jeremy D Heidel; Michael A Collingwood; Mark E Davis; John J Rossi; Mark A Behlke
Journal:  Nucleic Acids Res       Date:  2005-07-26       Impact factor: 16.971

Review 10.  Long-range control of gene expression: emerging mechanisms and disruption in disease.

Authors:  Dirk A Kleinjan; Veronica van Heyningen
Journal:  Am J Hum Genet       Date:  2004-11-17       Impact factor: 11.025

View more
  5 in total

1.  Mutational analysis reveals a noncontractile but interactive role of actin and profilin in viral RNA-dependent RNA synthesis.

Authors:  Mary Harpen; Tiasha Barik; Alla Musiyenko; Sailen Barik
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

2.  Human ribosomal protein L13a is dispensable for canonical ribosome function but indispensable for efficient rRNA methylation.

Authors:  Sujan Chaudhuri; Keyur Vyas; Purvi Kapasi; Anton A Komar; Jonathan D Dinman; Sailen Barik; Barsanjit Mazumder
Journal:  RNA       Date:  2007-10-05       Impact factor: 4.942

3.  Extraribosomal l13a is a specific innate immune factor for antiviral defense.

Authors:  Barsanjit Mazumder; Darshana Poddar; Abhijit Basu; Ravinder Kour; Valentina Verbovetskaya; Sailen Barik
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

4.  siRNA for Influenza Therapy.

Authors:  Sailen Barik
Journal:  Viruses       Date:  2010-07-09       Impact factor: 5.818

5.  RNAi Therapeutic Platforms for Lung Diseases.

Authors:  Yu Fujita; Fumitaka Takeshita; Kazuyoshi Kuwano; Takahiro Ochiya
Journal:  Pharmaceuticals (Basel)       Date:  2013-02-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.